Large Molecule Drug Substance CDMO Market Size, Share & Trends Analysis Report By Services (Contract Manufacturing, Contract Development), By Source (Mammalian, Microbial), By End-user, And Segment Forecasts, 2022 - 2030

Large Molecule Drug Substance CDMO Market Growth & Trends

The global large molecule drug substance CDMO market size is expected to reach USD 22.1 billion by 2030, registering a CAGR of 8.6% during the forecast period, according to a new report by Grand View Research, Inc. The rising incidence of infectious diseases and the high demand for novel therapeutics are the key factors driving the market growth. Contract manufacturing is one of the major steps in large molecule production and accounts for a sizable portion of the large molecule drug substance market. The mode of manufacturing is an important factor to consider as it represents the sector’s outsourcing and in-house activities.

Companies are still choosing to outsource services due to the high cost and delay in time. This has resulted in a greater proportion of large molecules being outsourced by the firms. A Contract Development & Manufacturing Organization (CDMO) is a company that provides a comprehensive range of services to the pharmaceutical industry, from drug development to manufacturing. CDMOs provide critical services by incorporating third-party projects and offering their knowledge, development, and manufacturing capabilities. Before the COVID-19 pandemic, large molecule drug investment was increasing as they offer a plethora of new treatment options.

The valuation of biologics became clearer during the race to develop therapeutics and vaccines against the SARS-CoV-2 virus. The demand for both high-volume and high-quality CGMP drug substance and drug product manufacturing services has risen dramatically, particularly for CDMOs capable of providing a wide range of COVID-19 vaccine technologies and, to a lesser extent, therapeutic monoclonal antibody products.

Large Molecule Drug Substance CDMO Market Report Highlights

• The contract manufacturing segment dominated the market with a revenue share of 68.0% in 2021
• Based on sources, the mammalian segment accounted for the largest revenue share in 2021. This category will expand as more complex biologics, such as bi- and tri-specific antibodies, and antibody-drug conjugates are evolved
• Based on end-users, the biotech companies segment led the global market in 2021 accounting for the largest revenue share. Rising R&D investments by the firms for large molecules drive the growth of this segment
• Asia Pacific is projected to witness the fastest CAGR during the forecast years. The presence of the target population & a low-cost, skilled workforce, and changes in the regulatory scenario are the key factors driving the market growth